Germany’s privately-held immatics biotechnologies GmbH has received 22 million euros ($29 million) to complete a Series D financing round, adding to 12 million euros it received in October as part of a total 34 million-euro funding round.
The Series D funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, and AT Impf GmbH and others.
Phase III trial to continue research
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze